Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Oncotelic Therapeutics, Inc. quarterly Debt-to-equity history and growth rate for Q3 2024.
Oncotelic Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 165 %.
Debt-to-equity, Quarterly (%)
Period
Value
YoY Chg
Change %
Date
Q3 2024
165
Sep 30, 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.